{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:35:37Z","timestamp":1794317737509,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006484","name":"AbbVie Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tau seed amplification assays (SAAs) directly measure the seeding activity of tau and would therefore be ideal biomarkers for clinical trials targeting seeding-competent tau in Alzheimer\u2019s disease (AD). However, the precise relationship between tau seeding measured by SAA and the levels of pathological forms of tau in the AD brain remains unknown. We developed a new tau SAA based on full-length 0N3R tau with sensitivity in the low fg\/ml range and used it to characterize 103 brain samples from three independent cohorts. Tau seeding clearly discriminated between AD and control brain samples. Interestingly, seeding was absent in Progressive Supranuclear Palsy (PSP) putamen, suggesting that our tau SAA did not amplify 4R tau aggregates from PSP brain. The specificity of our tau SAA for AD brain was further supported by analysis of matched hippocampus and cerebellum samples. While seeding was detected in hippocampus from Braak stages I-II, no seeding was present in AD cerebellum that is devoid of tau inclusions. Analysis of 40 middle frontal gyrus samples encompassing all Braak stages showed that tau SAA seeding activity gradually increased with Braak stage. This relationship between seeding activity and the presence of tau inclusions in AD brain was further supported by robust correlations between tau SAA results and the levels of phosphorylated tau212\/214, phosphorylated tau181, aggregated tau, and sarkosyl-insoluble tau. Strikingly, we detected tau seeding in the middle frontal gyrus already at Braak stage II-III, suggesting that tau SAA can detect tau pathology earlier than conventional immunohistochemical staining. In conclusion, our data suggest a quantitative relationship between tau seeding activity and pathological forms of tau in the human brain and provides an important basis for further development of tau SAA for accessible human samples.<\/jats:p>","DOI":"10.1186\/s40478-023-01676-w","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T06:02:28Z","timestamp":1699941748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tau seed amplification assay reveals relationship between seeding and pathological forms of tau in Alzheimer\u2019s disease brain"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-0051","authenticated-orcid":false,"given":"Bryan","family":"Frey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar E.","family":"Ehrnhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Striebinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Biesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Barghorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland G.","family":"Heym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"key":"1676_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259","journal-title":"Acta Neuropathol"},{"key":"1676_CR2","doi-asserted-by":"publisher","first-page":"E4376","DOI":"10.1073\/pnas.1411649111","volume":"111","author":"BB Holmes","year":"2014","unstructured":"Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC et al (2014) Proteopathic tau seeding predicts tauopathy in vivo. Proc National Acad Sci 111:E4376\u2013E4385","journal-title":"Proc National Acad Sci"},{"key":"1676_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/B978-0-444-63945-5.00016-7","volume":"153","author":"LC Walker","year":"2018","unstructured":"Walker LC (2018) Chapter 16 Prion-like mechanisms in Alzheimer disease. Handb Clin Neurol 153:303\u2013319","journal-title":"Handb Clin Neurol"},{"key":"1676_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s00415-021-10790-5","volume":"269","author":"J Pleen","year":"2022","unstructured":"Pleen J, Townley R (2022) Alzheimer\u2019s disease clinical trial update 2019\u20132021. J Neurol 269:1038\u20131051","journal-title":"J Neurol"},{"key":"1676_CR5","doi-asserted-by":"publisher","first-page":"P252","DOI":"10.1016\/j.jalz.2019.06.077","volume":"15","author":"WR Galpern","year":"2019","unstructured":"Galpern WR, Mercken M, Kolen KV, Timmers M, Haeverans K, Janssens L et al (2019) A single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacody-namics of the anti-phospho-tau antibody JNJ-63733657 in healthy subjects. Alzheimer\u2019s Dementia 15:P252\u2013P253","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1676_CR6","first-page":"S127","volume":"8","author":"W Luca","year":"2021","unstructured":"Luca W, Foster K, Clure KM, Jefson M, Ahlijanian M, Altstiel L (2021) Final Data from a phase 1 single-ascending dose trial of PNT001, a monoclonal antibody uniquely recognizing cis-PT231 Tau for treatment of tauopathies. J Prev Alzheimer\u2019s Dis 8:S127","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1676_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bbadis.2004.09.010","volume":"1739","author":"M von Bergen","year":"2005","unstructured":"von Bergen M, Barghorn S, Biernat J, Mandelkow E-M, Mandelkow E (2005) Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochimica Et Biophysica Acta Bba - Mol Basis Dis 1739:158\u2013166","journal-title":"Biochimica Et Biophysica Acta Bba - Mol Basis Dis"},{"key":"1676_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J et al (2022) Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimer\u2019s Dementia Transl Res Clin Interventions 8:e12295","journal-title":"Alzheimer\u2019s Dementia Transl Res Clin Interventions"},{"key":"1676_CR9","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954\u2013963","journal-title":"Nat Med"},{"key":"1676_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B et al (2019) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. Embo Mol Med 11:e11170","journal-title":"Embo Mol Med"},{"key":"1676_CR11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G et al (2020) Diagnostic performance of RO948 F 18 Tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. Jama Neurol 77:955\u2013965","journal-title":"Jama Neurol"},{"key":"1676_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00401-018-1855-6","volume":"136","author":"SK Kaufman","year":"2018","unstructured":"Kaufman SK, Tredici KD, Thomas TL, Braak H, Diamond MI (2018) Tau seeding activity begins in the transentorhinal\/entorhinal regions and anticipates phospho-tau pathology in Alzheimer\u2019s disease and PART. Acta Neuropathol 136:57\u201367","journal-title":"Acta Neuropathol"},{"key":"1676_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00401-016-1644-z","volume":"133","author":"JL Furman","year":"2017","unstructured":"Furman JL, Vaquer-Alicea J, White CL, Cairns NJ, Nelson PT, Diamond MI (2017) Widespread tau seeding activity at early Braak stages. Acta Neuropathol 133:91\u2013100","journal-title":"Acta Neuropathol"},{"key":"1676_CR14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV et al (2020) Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat Med 26:1256\u20131263","journal-title":"Nat Med"},{"key":"1676_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fnins.2018.00267","volume":"12","author":"SL DeVos","year":"2018","unstructured":"DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A et al (2018) Synaptic Tau seeding precedes tau pathology in human Alzheimer\u2019s disease brain. Front Neurosci-switz 12:267","journal-title":"Front Neurosci-switz"},{"key":"1676_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24716","volume":"80","author":"S Takeda","year":"2016","unstructured":"Takeda S, Commins C, DeVos SL, Nobuhara CK, Wegmann S, Roe AD et al (2016) Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer\u2019s disease mouse model and human patients. Ann Neurol 80:355\u2013367","journal-title":"Ann Neurol"},{"key":"1676_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00401-017-1692-z","volume":"133","author":"E Saijo","year":"2017","unstructured":"Saijo E, Ghetti B, Zanusso G, Oblak A, Furman JL, Diamond MI et al (2017) Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid. Acta Neuropathol 133:751\u2013765","journal-title":"Acta Neuropathol"},{"key":"1676_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00401-018-1947-3","volume":"137","author":"A Kraus","year":"2019","unstructured":"Kraus A, Saijo E, Metrick MA, Newell K, Sigurdson CJ, Zanusso G et al (2019) Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol 137:585\u2013598","journal-title":"Acta Neuropathol"},{"key":"1676_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108843","volume":"34","author":"Y Carlomagno","year":"2021","unstructured":"Carlomagno Y, Manne S, DeTure M, Prudencio M, Zhang Y-J, Al-Shaikh RH et al (2021) The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. Cell Rep 34:108843","journal-title":"Cell Rep"},{"key":"1676_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","volume":"139","author":"E Saijo","year":"2020","unstructured":"Saijo E, Metrick MA, Koga S, Parchi P, Litvan I, Spina S et al (2020) 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol 139:63\u201377","journal-title":"Acta Neuropathol"},{"key":"1676_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40478-021-01185-8","volume":"9","author":"BD Hitt","year":"2021","unstructured":"Hitt BD, Vaquer-Alicea J, Manon VA, Beaver JD, Kashmer OM, Garcia JN et al (2021) Ultrasensitive tau biosensor cells detect no seeding in Alzheimer\u2019s disease CSF. Acta Neuropathologica Commun 9:99","journal-title":"Acta Neuropathologica Commun"},{"key":"1676_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.2294","volume":"17","author":"R Atarashi","year":"2011","unstructured":"Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D et al (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17:175\u2013178","journal-title":"Nat Med"},{"key":"1676_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001217","volume":"6","author":"JM Wilham","year":"2010","unstructured":"Wilham JM, Orr\u00fa CD, Bessen RA, Atarashi R, Sano K, Race B et al (2010) Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. Plos Pathog 6:e1001217","journal-title":"Plos Pathog"},{"key":"1676_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","volume":"6","author":"BR Groveman","year":"2018","unstructured":"Groveman BR, Orr\u00f9 CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B et al (2018) Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC. Acta Neuropathologica Commun 6:7","journal-title":"Acta Neuropathologica Commun"},{"key":"1676_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41531-021-00242-2","volume":"7","author":"A Kuzkina","year":"2021","unstructured":"Kuzkina A, Bargar C, Schmitt D, R\u00f6\u00dfle J, Wang W, Schubert A-L et al (2021) Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: a two-laboratory study. Npj Park Dis 7:99","journal-title":"Npj Park Dis"},{"key":"1676_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","volume":"9","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L, Giaisi S, Groveman BR, Farris CM et al (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathologica Commun 9:179","journal-title":"Acta Neuropathologica Commun"},{"issue":"9","key":"1676_CR27","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge A, Bunk J, Schaeffer E, Drobny A, Xiang W, Knacke H et al (2022) Detection of neuron-derived pathological \u03b1-synuclein in blood. Brain. 145(9):3058\u20133071","journal-title":"Brain."},{"key":"1676_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno S, Imamichi-Tatano Y et al (2023) Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29:1448\u20131455","journal-title":"Nat Med"},{"key":"1676_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S et al (2016) Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3:812\u2013818","journal-title":"Ann Clin Transl Neurol"},{"key":"1676_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E, Farris CM, Ma Y, Urenia PA et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417","journal-title":"Lancet Neurol"},{"key":"1676_CR31","doi-asserted-by":"crossref","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. (2023) Towards a Biological Definition of Parkinson\u2019s Disease","DOI":"10.20944\/preprints202304.0108.v1"},{"key":"1676_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-020-0887-z","volume":"8","author":"MA Metrick","year":"2020","unstructured":"Metrick MA, do Ferreira N C, Saijo E, Kraus A, Newell K, Zanusso G et al (2020) A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathologica Commun. 8:22","journal-title":"Acta Neuropathologica Commun."},{"key":"1676_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.945875","volume":"14","author":"L Wu","year":"2022","unstructured":"Wu L, Wang Z, Lad S, Gilyazova N, Dougharty DT, Marcus M et al (2022) Selective detection of misfolded Tau from postmortem Alzheimer\u2019s Disease brains. Front Aging Neurosci 14:945875","journal-title":"Front Aging Neurosci"},{"key":"1676_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/19336896.2020.1832946","volume":"14","author":"JM Tennant","year":"2020","unstructured":"Tennant JM, Henderson DM, Wisniewski TM, Hoover EA (2020) RT-QuIC detection of tauopathies using full-length tau substrates. Prion 14:249\u2013256","journal-title":"Prion"},{"key":"1676_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02574-0","author":"M Manca","year":"2023","unstructured":"Manca M, Standke HG, Browne DF, Huntley ML, Thomas OR, Orr\u00fa CD et al (2023) Tau seeds occur before earliest Alzheimer\u2019s changes and are prevalent across neurodegenerative diseases. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-023-02574-0","journal-title":"Acta Neuropathol"},{"key":"1676_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s40478-019-0831-2","volume":"7","author":"K Schlegel","year":"2019","unstructured":"Schlegel K, Awwad K, Heym RG, Holzinger D, Doell A, Barghorn S et al (2019) N368-Tau fragments generated by legumain are detected only in trace amount in the insoluble Tau aggregates isolated from AD brain. Acta Neuropathologica Commun 7:177","journal-title":"Acta Neuropathologica Commun"},{"key":"1676_CR37","doi-asserted-by":"publisher","first-page":"34389","DOI":"10.1074\/jbc.M114.611368","volume":"289","author":"K Tepper","year":"2014","unstructured":"Tepper K, Biernat J, Kumar S, Wegmann S, Timm T, H\u00fcbschmann S et al (2014) Oligomer formation of Tau protein hyperphosphorylated in cells*. J Biol Chem 289:34389\u201334407","journal-title":"J Biol Chem"},{"key":"1676_CR38","doi-asserted-by":"publisher","first-page":"14885","DOI":"10.1021\/bi026469j","volume":"41","author":"S Barghorn","year":"2002","unstructured":"Barghorn S, Mandelkow E (2002) Toward a unified scheme for the aggregation of Tau into Alzheimer paired helical filaments \u2020. Biochemistry 41:14885\u201314896","journal-title":"Biochemistry"},{"key":"1676_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","volume":"598","author":"Y Shi","year":"2021","unstructured":"Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A et al (2021) Structure-based classification of tauopathies. Nature 598:359\u2013363","journal-title":"Nature"},{"key":"1676_CR40","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1021\/bi2004685","volume":"50","author":"PD Dinkel","year":"2011","unstructured":"Dinkel PD, Siddiqua A, Huynh H, Shah M, Margittai M (2011) Variations in filament conformation dictate seeding barrier between three- and four-repeat Tau. Biochemistry-us 50:4330\u20134336","journal-title":"Biochemistry-us"},{"key":"1676_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084812","volume":"9","author":"K Cheng","year":"2014","unstructured":"Cheng K, Sloan A, Avery KM, Coulthart M, Carpenter M, Knox JD (2014) Exploring physical and chemical factors influencing the properties of recombinant prion protein and the real-time quaking-induced conversion (RT-QuIC) assay. PLoS ONE 9:e84812","journal-title":"PLoS ONE"},{"key":"1676_CR42","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/v8050140","volume":"8","author":"CD Orr\u00fa","year":"2016","unstructured":"Orr\u00fa CD, Hughson AG, Groveman BR, Campbell KJ, Anson KJ, Manca M et al (2016) Factors that improve RT-QuIC detection of prion seeding activity. Viruses 8:140","journal-title":"Viruses"},{"key":"1676_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","volume":"154","author":"JL Guo","year":"2013","unstructured":"Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B et al (2013) Distinct \u03b1-synuclein strains differentially promote Tau inclusions in neurons. Cell 154:103\u2013117","journal-title":"Cell"},{"key":"1676_CR44","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/s41598-022-06846-9","volume":"12","author":"L Torres-Garcia","year":"2022","unstructured":"Torres-Garcia L, Domingues JMP, Brandi E, Haikal C, Mudannayake JM, Br\u00e1s IC et al (2022) Monitoring the interactions between alpha-synuclein and Tau in vitro and in vivo using bimolecular fluorescence complementation. Sci Rep-uk 12:2987","journal-title":"Sci Rep-uk"},{"key":"1676_CR45","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1039\/D1CS00127B","volume":"51","author":"G Limorenko","year":"2021","unstructured":"Limorenko G, Lashuel HA (2021) Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. Chem Soc Rev 51:513\u2013565","journal-title":"Chem Soc Rev"},{"key":"1676_CR46","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P et al (2020) Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell 183:1699-1713.e13","journal-title":"Cell"},{"key":"1676_CR47","first-page":"3372","volume":"28","author":"H Braak","year":"2018","unstructured":"Braak H, Tredici KD (2018) Spreading of Tau pathology in sporadic Alzheimer\u2019s disease along cortico-cortical top-down connections. Cereb Cortex New York Ny 28:3372\u20133384","journal-title":"Cereb Cortex New York Ny"},{"key":"1676_CR48","doi-asserted-by":"publisher","first-page":"23029","DOI":"10.1073\/pnas.1909322116","volume":"116","author":"MA Metrick","year":"2019","unstructured":"Metrick MA, do Ferreiran C, Saijo E, Hughson AG, Kraus A, Orr\u00fa C et al (2019) Million-fold sensitivity enhancement in proteopathic seed amplification assays for biospecimens by Hofmeister ion comparisons. Proc National Acad Sci 116:23029\u201323039","journal-title":"Proc National Acad Sci"},{"key":"1676_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/pro.4257","volume":"31","author":"H Shahpasand-Kroner","year":"2022","unstructured":"Shahpasand-Kroner H, Portillo J, Lantz C, Seidler PM, Sarafian N, Loo JA et al (2022) Three-repeat and four-repeat tau isoforms form different oligomers. Protein Sci 31:613\u2013627","journal-title":"Protein Sci"},{"key":"1676_CR50","doi-asserted-by":"crossref","unstructured":"Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, et al. (2021) Structure-based classification of tauopathies. Nature [Internet]. 598:359\u2013363. Available from: https:\/\/www.nature.com\/articles\/s41586-021-03911-7.pdf","DOI":"10.1038\/s41586-021-03911-7"},{"key":"1676_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41586-018-0454-y","volume":"561","author":"B Falcon","year":"2018","unstructured":"Falcon B, Zhang W, Murzin AG, Murshudov G, Garringer HJ, Vidal R et al (2018) Structures of filaments from Pick\u2019s disease reveal a novel tau protein fold. Nature 561:137\u2013140","journal-title":"Nature"},{"key":"1676_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-018-1914-z","volume":"136","author":"B Falcon","year":"2018","unstructured":"Falcon B, Zhang W, Schweighauser M, Murzin AG, Vidal R, Garringer HJ et al (2018) Tau filaments from multiple cases of sporadic and inherited Alzheimer\u2019s disease adopt a common fold. Acta Neuropathol 136:699\u2013708","journal-title":"Acta Neuropathol"},{"key":"1676_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ et al (2017) Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547:185\u2013190","journal-title":"Nature"},{"key":"1676_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40478-019-0708-4","volume":"7","author":"M Ebashi","year":"2019","unstructured":"Ebashi M, Ito Y, Uematsu M, Nakamura A, Hirokawa K, Kamei S et al (2019) How to demix Alzheimer-type and PSP-type tau lesions out of their mixture -hybrid approach to dissect comorbidity-. Acta Neuropathologica Commun 7:71","journal-title":"Acta Neuropathologica Commun"},{"key":"1676_CR55","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/brain\/awm104","volume":"130","author":"DR Williams","year":"2007","unstructured":"Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ et al (2007) Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson\u2019s syndrome. Brain 130:1566\u20131576","journal-title":"Brain"},{"key":"1676_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.684523","volume":"12","author":"M Willroider","year":"2021","unstructured":"Willroider M, Roeber S, Horn AKE, Arzberger T, Scheifele M, Respondek G et al (2021) Superiority of formalin-fixed paraffin-embedded brain tissue for in vitro assessment of progressive supranuclear palsy tau pathology with [18F]PI-2620. Front Neurol 12:684523","journal-title":"Front Neurol"},{"key":"1676_CR57","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G et al (2022) Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging 2:526\u2013535","journal-title":"Nat Aging"},{"key":"1676_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Tredici KD (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389\u2013404","journal-title":"Acta Neuropathol"},{"key":"1676_CR59","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S et al (2019) Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimer\u2019s Dementia 15:644\u2013654","journal-title":"Alzheimer\u2019s Dementia"}],"updated-by":[{"DOI":"10.1186\/s40478-024-01825-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000}}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01676-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T10:16:18Z","timestamp":1721038578000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01676-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01676-w","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40478-024-01825-9","URL":"https:\/\/doi.org\/10.1186\/s40478-024-01825-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BF, DH, DEE, KT, AS, SBi, LG, MO, SBa, RH are employees of AbbVie. FW and GH co-supervised the scientific work (no funding to disclose). The design, study conduct and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review and approval of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}